Table 1.
Demographic characteristics and clinical/laboratory features analyzed.
| 95% CI | ||||||
| Variable | Live (n = 78) | Dead (n = 25) | OR | Lower | Upper | P |
| Gender (female), n (%) | 51 (65.4) | 15 (60) | 0.79 | 0.32 | 2.01 | .625∗ |
| Age at diagnosis, yrs, mean ± SD | 41 ± 16.5 | 51.3 ± 16.1 | 1.04 | 1.01 | 1.07 | .008∗∗ |
| Disease duration, yrs, mean ± SD | 10.8 ± 6.1 | 8.4 ± 6 | 0.94 | 0.86 | 1.01 | .009∗∗ |
| c-ANCA, n (%) | 46 (59) | 14 (56) | 0.89 | 0.36 | 2.20 | .793∗ |
| p-ANCA, n (%) | 19 (24.4) | 4 (16) | 0.59 | 0.18 | 1.94 | .382∗ |
| BVAS, median (IQR) | 2 (0;4) | 8 (2;12) | 1.21 | 1.09 | 1.34 | .001 |
| VDI, median (IQR) | (3 (2;5) | 6 (3;8.5) | 1.43 | 1.18 | 1.73 | <.001 |
| Hemoglobin, g/dL, median (IQR) | 13.4 (12.5;14.3) | 11.3 (8.5;13.1) | 0.49 | 0.35 | 0.69 | <.001 |
| Leukocytes (103/mm3), median (IQR) | 6.38 (5.32;9.08) | 9.47 (6.02;11.79) | 1.14 | 0.99 | 1.32 | .037 |
| Neutrophils median (IQR) | 4.20 (3.11;6.40) | 6.50 (4.83;9.10) | 1.29 | 1.08 | 1.54 | .002 |
| Lymphocytes, median (IQR) | 1.55 (1.05;2.15) | 1.71 (0.680;2.62) | 0.95 | 0.53 | 1.70 | .818 |
| Platelets, 103/μL, median (IQR) | 232 (210;304) | 217 (131.5;295;3) | 0.99 | 0.99 | 1.00 | .125 |
| Creatinine, mg/dL, median (IQR) | 0.9 (0.7;1.1) | 1.6 (0.9;3.9) | 1.39 | 1.09 | 1.76 | <.001 |
| CRP, mg/L, median (IQR) | 2.9 (1.3;6.1) | 33.1 (6.1;142.1) | 1.07 | 1.02 | 1.13 | <.001 |
| ESR (mm/1st h), median (IQR) | 14 (5;25) | 31 (7.3;64) | 1.03 | 1.01 | 1.05 | .037 |
| Prednisone dose, mg/d, median (IQR) | 2.5 (0;10) | 15 (1.3;30) | 1.03 | 1.00 | 1.05 | .014 |
Mann–Whitney's U test.
BVAS = Birmingham vasculitis activity score, CRP = C-reactive protein, ESR = erythrocyte sedimentation ratio, VDI = vasculitis damage index.
∗
Chi-square's test.
∗∗
Student's t test.